mycophenolic-acid and Pulmonary-Embolism

mycophenolic-acid has been researched along with Pulmonary-Embolism* in 1 studies

Other Studies

1 other study(ies) available for mycophenolic-acid and Pulmonary-Embolism

ArticleYear
[Pulmonary embolism in a girl with nephrotic syndrome and factor V Leiden - case report].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2018, Sep-21, Volume: 45, Issue:267

    Thromboembolic complications are found in 2-3% of children with nephrotic syndrome (NS); this increased risk is caused by hypovolemia, hemoconcentration, increased number and activity of platelets, hyperfibrinogenemia and loss of coagulation inhibitors. Risk is even higher in case of additional factors e.g. congenital thrombophilia.. Girl with NS aged 17 11/12 years was admitted to hospital due to respiratory tract infection with cough and back pain. NS started 9 months earlier and she had two bouts of disease, and was treated only with prednisone (current dose - 60 mg/48h). On admission she was without any abnormalities on auscultation, with BP 111/65 mmHg, HR 80 bpm, satO2 99%. Lab results showed the increase of WBC 18.3×103/μL, D-dimers 23038 μg/L and proteinuria 900 mg/dL. Other values of examined parameters were in normal limits. Chest X-ray and ECG were also normal. Presumptive diagnosis of pulmonary embolism was made and the patient was given 1000IU of antithrombin III and nadroparine (2x90IU/kg/24h s.c.). In ECHO the occlusion of left pulmonary artery and preserved blood flow in right were revealed. In angioCT clot nearly filling lumen of left pulmonary artery, clot in intermediate part of right pulmonary artery, and focus of pulmonary infarction in 10th segment of left lung were found. Doppler USG of lower limb veins did not reveal thrombi or perforator vein incompetence. Treatment with nadroparine was continued, and rapid improvement of clinical condition and disappearance of pain and cough were observed. Mycophenolate mofetil was added, which resulted in subsidence of proteinuria. Rivaroxaban was used in prophylaxis of recurrences of thromboembolism. Tests for thrombophilia revealed factor V Leiden in patient.

    Topics: Adolescent; Anticoagulants; Antithrombin III; Factor V; Female; Humans; Mycophenolic Acid; Nadroparin; Nephrotic Syndrome; Pulmonary Embolism; Thrombophilia

2018